Black Rock Inc. Chembio Diagnostics, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.25 - $0.45 $48 - $86	-193 Reduced 0.09%	206,051 $90,000
Q4 2022 Feb 13, 2023	SELL	$0.2 - $0.33 $37 - $61	-185 Reduced 0.09%	206,244 $45,000
Q3 2022 Nov 14, 2022	SELL	$0.35 - $1.1 $100 - $315	-287 Reduced 0.14%	206,429 $74,000
Q2 2022 Aug 12, 2022	SELL	$0.45 - $0.8 $34,119 - $60,657	-75,822 Reduced 26.84%	206,716 $134,000
Q1 2022 May 12, 2022	BUY	$0.66 - $1.23 $3,076 - $5,733	4,661 Added 1.68%	282,538 $231,000
Q4 2021 Feb 10, 2022	BUY	$1.09 - $2.55 $11,629 - $27,205	10,669 Added 3.99%	277,877 $316,000
Q3 2021 Nov 09, 2021	BUY	$2.06 - $5.34 $139,995 - $362,901	67,959 Added 34.11%	267,208 $668,000
Q2 2021 Aug 11, 2021	BUY	$2.88 - $5.64 $573,837 - $1.12 Million	199,249 New	199,249 $593,000

Ticker CEMI
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 30,224,600
Description
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, la...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.